Literature DB >> 15702319

[Results of the "Ocular hypertension treatment study"].

N Pfeiffer1.   

Abstract

Ocular hypertension (OHT) is defined as intraocular pressure (IOP) elevated above normal levels which occurs without detectable damage to the papilla or visual field. It is considered to be the most important risk factor for developing primary open-angle glaucoma (POAG). The "Ocular hypertension treatment study" (OHTS) addresses the issue of whether lowering IOC before damage to the papilla or visual field occurs can hinder their development and whether OHT can be treated categorically. This randomized, prospective, nonmasked and non-placebo-controlled, multicenter study documents the protective effect of prophylactic lowering of IOC and identifies and explains the risk factors for developing POAG. These include advancing age, reduced corneal thickness, increased pattern standard deviations in white-on-white perimetry, and elevated vertical or horizontal cup to disc ratio. Due to the large individual differences in risk distribution and the very high costs of treating OHT, the question of whether OHT should be treated on principle remains open in the OHTS. This decision must be made on an individual basis after each patient's risk has been assessed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15702319     DOI: 10.1007/s00347-004-1150-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  13 in total

1.  Contralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the ocular hypertension treatment study.

Authors:  J Piltz; R Gross; D H Shin; J A Beiser; D A Dorr; M A Kass; M O Gordon
Journal:  Am J Ophthalmol       Date:  2000-10       Impact factor: 5.258

2.  Answers from the ocular hypertension treatment study.

Authors:  Paul Palmberg
Journal:  Arch Ophthalmol       Date:  2002-06

3.  Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Ocular Hypertension Treatment Study Group.

Authors:  J L Keltner; C A Johnson; J M Quigg; K E Cello; M A Kass; M O Gordon
Journal:  Arch Ophthalmol       Date:  2000-09

4.  The Ocular Hypertension Treatment Study: reproducibility of cup/disk ratio measurements over time at an optic disc reading center.

Authors:  William J Feuer; Richard K Parrish; Joyce C Schiffman; Douglas R Anderson; Donald L Budenz; Maria-Cristina Wells; Ditte J Hess; Michael A Kass; Mae O Gordon
Journal:  Am J Ophthalmol       Date:  2002-01       Impact factor: 5.258

5.  Long-term effects of timolol therapy in ocular hypertension: a double-masked, randomised trial.

Authors:  A Heijl; B Bengtsson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2000-11       Impact factor: 3.117

6.  The Ocular Hypertension Treatment Study: design and baseline description of the participants.

Authors:  M O Gordon; M A Kass
Journal:  Arch Ophthalmol       Date:  1999-05

7.  The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma.

Authors:  Mae O Gordon; Julia A Beiser; James D Brandt; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Michael A Kass
Journal:  Arch Ophthalmol       Date:  2002-06

8.  The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

Authors:  Michael A Kass; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Mae O Gordon
Journal:  Arch Ophthalmol       Date:  2002-06

9.  A comparison of treated and untreated glaucoma suspects.

Authors:  M Schulzer; S M Drance; G R Douglas
Journal:  Ophthalmology       Date:  1991-03       Impact factor: 12.079

10.  A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects.

Authors:  D L Epstein; J H Krug; E Hertzmark; L L Remis; D J Edelstein
Journal:  Ophthalmology       Date:  1989-10       Impact factor: 12.079

View more
  4 in total

1.  Intraocular pressure measurement with Corvis ST in comparison with applanation tonometry and Tomey non-contact tonometry.

Authors:  Jan Luebke; L Bryniok; M Neuburger; J F Jordan; D Boehringer; T Reinhard; T Wecker; A Anton
Journal:  Int Ophthalmol       Date:  2019-04-09       Impact factor: 2.031

Review 2.  Glaucoma: recent advances in the involvement of autoimmunity.

Authors:  Maria Ida Rizzo; Antonio Greco; Armando De Virgilio; Andrea Gallo; Luciano Taverniti; Massimo Fusconi; Michela Conte; Giulio Pagliuca; Rosaria Turchetta; Marco de Vincentiis
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

3.  Autoantibody Biomarker Discovery in Primary Open Angle Glaucoma Using Serological Proteome Analysis (SERPA).

Authors:  Vanessa M Beutgen; Natarajan Perumal; Norbert Pfeiffer; Franz H Grus
Journal:  Front Immunol       Date:  2019-03-07       Impact factor: 7.561

4.  Serum and antibodies of glaucoma patients lead to changes in the proteome, especially cell regulatory proteins, in retinal cells.

Authors:  Katharina Bell; Sebastian Funke; Norbert Pfeiffer; Franz H Grus
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.